Lupin enters into exclusive licensing agreement with Irom

28 Aug 2022 , 01:34 AM

Lupin announced that it has entered into an exclusive licensing agreement with Irom Group Co Irom a leading pharmaceutical company in Japan Under the terms of the Agreement Irom will conduct clinical trials along with Lupin register distribute and market biosimilar Denosumab in Japan on an exclusive basis Denosumab is indicated for the treatment of postmenopausal women with osteoporosis at high risk of fracture and prevention of skeletal-related events in patients with bone metastases from solid tumors among other indications Following the completion of the clinical trial and receipt of marketing authorization from PMDA in Japan Irom will exclusively commercialize the product in Japan As part of the agreement Lupin will receive multiple milestone payments Currently Denosumab is available under two brands Pralia and Ranmark with a market size of approximately USD 500 million in Japan